US EditionNew Strategy for Difficult-to-Treat Mesothelioma: Immunotherapy and ctDNA Insights
A Phase II trial at Johns Hopkins shows immunotherapy before surgery for operable mesothelioma is feasible and safe, with novel tumor DNA blood testing aiding treatment decisions.
4 Articles
4 Articles
Blood test spots hidden mesothelioma that scans can’t see
New research suggests that immunotherapy given before and after surgery could help patients with diffuse pleural mesothelioma, one of the most challenging cancers to treat. A phase II clinical trial tested immunotherapy in resectable cases, with promising results presented at the World Conference on Lung Cancer.
News Medical
Industrial NewsNew strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.
Clinical study deepens understanding of mesothelioma, opens the door to potential treatment options
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
